Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

IRDye800CW-nimotuzumab

A fluorescence imaging and contrast agent and immunoconjugate comprised of nimotuzumab, a humanized monoclonal antibody directed against the epidermal growth factor receptor (EGFR), conjugated to the near-infrared (NIR) fluorescent dye IRDye 800CW, with potential imaging use. Upon administration of IRDye800CW-nimotuzumab, the nimotuzumab moiety targets and binds to the extracellular domain of EGFR. Upon binding, IRDye 800 may be detected using NIR imaging, which facilitates the visualization and detection of EGFR-expressing tumor cells. EGFR is a receptor tyrosine kinase that may be overexpressed on the cell surfaces of various tumor types.
Synonym:IRDye800CW-labeled nimotuzumab
nimotuzumab-IRDye800CW
Search NCI's Drug Dictionary